Drug Profile
Vilanterol - GlaxoSmithKline/Theravance
Alternative Names: '444; 642444; GSK-642444; GW 642444; GW642444H; GW642444M; GW642444X; Vilanterol trifenatateLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Theravance
- Developer GlaxoSmithKline; GSK; Innoviva; Theravance
- Class Antiasthmatics; Chlorobenzenes; Ethers; Phenols; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic obstructive pulmonary disease
- Phase II Asthma
Most Recent Events
- 16 Apr 2021 Discontinued - Phase-I for Chronic obstructive pulmonary disease (Combination therapy, In volunteers) in United Kingdom (Inhalation)
- 16 Apr 2021 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in China (Inhalation)
- 16 Apr 2021 Discontinued - Phase-I for Chronic obstructive pulmonary disease (Monotherapy, In volunteers) in United Kingdom (Inhalation)